Adenoviral vector-mediated transient gene expression in primitive hematopoietic progenitor cells can provide a new approach for understanding their basic biology and for manipulating their properties in vitro and in vivo. Adenoviral vectors can transduce quiescent primitive hematopoietic progenitor cells efficiently, which is an advantage since most primitive hematopoietic progenitor and stem cells are nondividing in vivo. 1, 2 Using adenoviral vectors encoding reporter genes, it has been shown that hematopoietic progenitors can be transduced efficiently with adenoviral vectors, including colony-forming progenitor cells and the more primitive long-term culture-initiating cells. [1] [2] [3] [4] More importantly, recent data demonstrate that adenoviral vectors can transduce primitive human hematopotic progenitors that engraft in NOD/SCID mice and differentiate into many hematopoietic lineages in vivo. These cells are currently considered to be candidate human hematopoietic stem cells (SCIDrepopulating cells, SRC). 1 Adenoviral vector transgene expression can be improved in two ways. First, the uptake of adenoviral vectors could be made more efficient by using recombinant adenoviral fiber knobs that increase vector uptake or make it more efficient by binding to receptors on hem- atopoietic progenitors that are in high abundance. 5, 6 Second, the level and durability of transgene expression can be improved by generating larger amounts of stable transgene RNA. When it comes to uptake of vectors, the wild-type Ad5 fiber binds to the coxsackievirus and adenovirus receptor (CAR) for attachment 7 and requires integrin ␣ V ␤ 5 /␣ V ␤ 3 -mediated internalization. 8 Neither of these classes of molecules are expressed at sufficient levels for efficient adenoviral uptake into hematopoietic progenitor cells. 3 Extended co-incubation of hematopoietic progenitor cells with adenoviral vectors, high MOI and preincubation of adenoviral vectors with polycationic substances have been applied for sufficient adenoviral uptake into hematopoietic progenitor cells. [1] [2] [3] [4] After efficient uptake, adenoviral vector-mediated transgene expression in primitive hematopoietic progenitors is dependent on the regulatory control sequences and polyadenylation sequences in the expression cassette. In CD34 + cells, the LTR of the Moloney murine leukemia virus, 2,9 the CAR promoter, 3 the CMV promoter, 4,10-12 and the PGK-1 promoter 4 have been used for efficient transgene expression, whereas the LTR of the Rous sarcoma virus and the SR-␣ promoter from HTLV-1 have proven inefficient. 4 Since most of the CD34 + cells are lineage committed and the primitive progenitor cells including LTCICs 13 different 5Ј and 3Ј regulatory elements as described in Figure 1 were generated. We first studied the level of transgene expression in HeLa cells and K562 cells. As shown in Figure 2 , both HeLa cells and K562 cells were efficiently transduced by adenoviral vectors at an MOI of 100. Up to 90% of HeLa cells or 50% of K562 cells expressed EGFP. In HeLa cells, the Ad5xPGK-EGFP-SV40 and Ad5xHCMV-EGFP-SV40 vectors gave markedly higher levels of EGFP expression than the Ad5xPGK-EGFP-␤-globin vector. In K562 cells, the vector Ad5xPGK-EGFP-SV40 allowed the highest level of EGFP expression whereas the Ad5xHCMV-EGFP-SV40 and
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Ad5xPGK-EGFP-␤-globin vectors gave relatively lower levels of expression.
To study the level of adenoviral vector-mediated transgene expression in CD34
− cells, we set out to transduce CD34
+ cells from normal bone marrow or umbilical cord blood under serum-free culture conditions in the presence of MGDF, or MGDF, KL and FL. It has been demonstrated that in serum-free media, MGDF alone is capable of supporting the survival of primitive hematopoietic progenitor cells, 15 and the synergistic effect of MGDF, KL and FL is capable of inducing proliferation of these cells. 16 Transduced cells were then analyzed for 
CD38
− and CD34 + CD38 high subfractions, the Ad5xPGK-EGFP-␤-globin vector gave the highest percentage of EGFP expressing cells, whereas the Ad5xHCMV-EGFP-SV40 vector gave the lowest values. When the EGFP expression level per cell was compared within the EGFP expressing cells, the Ad5xPGK-EGFP-␤-globin vector gave two-fold higher EGFP expression than that of the Ad5xHCMV-EGFP-SV40 vector. We examined this trend in CD34 + cells from several bone marrow samples and umbilical cord blood samples. As shown in Table 1 , in all the donors tested, we repeatedly found higher percentages of CD34 
− cells, whereas the combination of HCMV promoter or PGK-1 promoter with SV40 polyadenylation in the adenoviral vectors tested, gave moderate levels of transgene expression.
Next, we studied the duration of adenoviral vectormediated transgene expression in primitive progenitors.
Cord blood CD34
+ cells were cultured under proliferating conditions and infected with the Ad5xPGK-EGFP-␤-globin vector or the Ad5xPGK-EGFP-SV40 vector. As shown in Figure 5a , the total cell numbers expanded 35-fold within 9 days. In parallel transduced cultures (Figure 5b ), EGFP expression was found to be highest at day 2 after transduction and decreased gradually from day 4 to day 6. At day 8 after transduction, only 2% of the total cells were CD34
+ with marginal EGFP expression. The Ad5xPGK-EGFP-␤-globin vector mediated a higher level of EGFP expression from 2 to 6 days after transduction, but did not give a longer duration of EGFP expression in CD34
+ cells compared with the other vectors. In summary, our findings demonstrate that the Ad5xPGK-EGFP-␤-globin vector allowed significantly high levels of transgene expression in CD34 +
CD38
− cells from cord blood or bone marrow both under survival conditions and proliferating conditions. Therefore, the PGK-1 promoter and the regulatory sequences consisting of IVS2 and polyadenylation sequences of ␤-globin gene are advantageous for high transgene expression levels in primitive CD34 +
− cells when used within the context of an adenoviral vector. Furthermore, we show that the regulatory sequences successfully used for transgene expression in transformed cell lines may not generate high levels of transgene expression in CD34 +
− cells. These results can provide a basis for future adenoviral vector design for transient gene expression in candidate human hematopoietic stem cells.
These results also show that high MOI is required for sufficient level of transgene expression in CD34 + CD38
− cells, which indicates that adenoviral vector uptake into CD34 + CD38 − cells is not efficient even in the presence of polycationic substances. Recent reports demonstrate that adenoviral vectors with genetically engineered fiber genes, which bind efficiently to cell surface molecules on CD34
+ cells can transduce CD34 + progenitor cells more efficiently than Ad5 vectors with unmodified fiber genes. 6, 17 The combined efforts of engineered fiber genes and optimal design of expression cassette in adenoviral vectors may accelerate the vector uptake kinetics, enhance the vector copy number and generate a higher level of transgene expression in primitive human hematopoietic cells. 
− and CD34 CD34 + cells from bone marrow of healthy donors or cord blood samples of normal deliveries were cultured and infected with adenoviral vectors as described in Figure 3 . Data for samples of BM1, BM2 and BM4 were derived from an average of two independent wells, data for samples of BM3, CB1 and CB2 were derived from single transduced wells. The experiment with CB2 CD34
+ cells as assessed 48 h after transduction; all other experiments were assessed 72 h after transduction. 
